Neurotoxicity of amyloid β-protein: synaptic and network dysfunction.

Evidence for an ever-expanding variety of molecular mediators of amyloid β-protein neurotoxicity (membrane lipids, receptor proteins, channel proteins, second messengers and related signaling cascades, cytoskeletal proteins, inflammatory mediators, etc.) has led to the notion that the binding of hydrophobic Aβ assemblies to cellular membranes triggers multiple effects affecting diverse pathways. It appears unlikely that there are only one or two cognate receptors for neurotoxic forms of Aβ and also that there are just one or two assembly forms of the peptide that induce neuronal dysfunction. Rather, various soluble (diffusible) oligomers of Aβ that may be in dynamic equilibrium with insoluble, fibrillar deposits (amyloid plaques) and that can bind to different components of neuronal and non-neuronal plasma membranes appear to induce complex patterns of synaptic dysfunction and network disorganization that underlie the intermittent but gradually progressive cognitive manifestations of the clinical disorder. Modern analyses of this problem utilize electrophysiology coupled with synaptic biochemistry and behavioral phenotyping of animal models to elucidate the affected circuits and assess the effects of potential therapeutic interventions.

[1]  R. Nicoll,et al.  Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[2]  Bertrand Z. Yeung,et al.  Vulnerability of Dentate Granule Cells to Disruption of Arc Expression in Human Amyloid Precursor Protein Transgenic Mice , 2005, The Journal of Neuroscience.

[3]  Julie Harris,et al.  Reversing EphB2 depletion rescues cognitive functions in Alzheimer model , 2011, Nature.

[4]  Meaghan Morris,et al.  The Many Faces of Tau , 2011, Neuron.

[5]  G. Collingridge,et al.  Mechanisms contributing to the deficits in hippocampal synaptic plasticity in mice lacking amyloid precursor protein , 1999, Neuropharmacology.

[6]  D. Bredesen,et al.  Abnormal neuronal networks and seizure susceptibility in mice overexpressing the APP intracellular domain , 2011, Neurobiology of Aging.

[7]  Roberto Malinow,et al.  Synaptic AMPA Receptor Plasticity and Behavior , 2009, Neuron.

[8]  A. Yang,et al.  Loss of endosomal/lysosomal membrane impermeability is an early event in amyloid Aβ1‐42 pathogenesis , 1998, Journal of neuroscience research.

[9]  C. Almeida,et al.  Oligomerization of Alzheimer's β-Amyloid within Processes and Synapses of Cultured Neurons and Brain , 2004, The Journal of Neuroscience.

[10]  Kristina D. Micheva,et al.  Oligomeric amyloid β associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques , 2009, Proceedings of the National Academy of Sciences.

[11]  P. Greengard,et al.  Intraneuronal Alzheimer abeta42 accumulates in multivesicular bodies and is associated with synaptic pathology. , 2002, The American journal of pathology.

[12]  D. Kullmann,et al.  Long-term synaptic plasticity in hippocampal interneurons , 2007, Nature Reviews Neuroscience.

[13]  Shaomin Li,et al.  Soluble Oligomers of Amyloid β Protein Facilitate Hippocampal Long-Term Depression by Disrupting Neuronal Glutamate Uptake , 2009, Neuron.

[14]  Shaomin Li,et al.  Soluble Aβ Oligomers Inhibit Long-Term Potentiation through a Mechanism Involving Excessive Activation of Extrasynaptic NR2B-Containing NMDA Receptors , 2011, The Journal of Neuroscience.

[15]  R. Malinow,et al.  AMPAR Removal Underlies Aβ-Induced Synaptic Depression and Dendritic Spine Loss , 2006, Neuron.

[16]  C. Haass,et al.  Trafficking and proteolytic processing of APP. , 2012, Cold Spring Harbor perspectives in medicine.

[17]  B. Penke,et al.  Amyloid β‐peptide interactions with neuronal and glial cell plasma membrane: binding sites and implications for Alzheimer's disease , 2004 .

[18]  P. Greengard,et al.  Regulation of NMDA receptor trafficking by amyloid-β , 2005, Nature Neuroscience.

[19]  H. Cai,et al.  BACE1, a Major Determinant of Selective Vulnerability of the Brain to Amyloid-β Amyloidogenesis, is Essential for Cognitive, Emotional, and Synaptic Functions , 2005, The Journal of Neuroscience.

[20]  D. Selkoe,et al.  Amyloid β-peptide is produced by cultured cells during normal metabolism , 1992, Nature.

[21]  Arthur Konnerth,et al.  Clusters of Hyperactive Neurons Near Amyloid Plaques in a Mouse Model of Alzheimer's Disease , 2008, Science.

[22]  A. Schmidt,et al.  Cellular cofactors for amyloid beta-peptide-induced cell stress. Moving from cell culture to in vivo. , 1999, The American journal of pathology.

[23]  Carl W. Cotman,et al.  Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of Pathogenesis , 2003, Science.

[24]  L. Mucke,et al.  Epilepsy and cognitive impairments in Alzheimer disease. , 2009, Archives of neurology.

[25]  C. Finch,et al.  Synaptic Targeting by Alzheimer's-Related Amyloid β Oligomers , 2004, The Journal of Neuroscience.

[26]  D. Selkoe,et al.  Biochemical and immunohistochemical analysis of an Alzheimer's disease mouse model reveals the presence of multiple cerebral Aβ assembly forms throughout life , 2009, Neurobiology of Disease.

[27]  D. Selkoe The molecular pathology of Alzheimer's disease , 1991, Neuron.

[28]  C. Almeida,et al.  β-Amyloid Accumulation Impairs Multivesicular Body Sorting by Inhibiting the Ubiquitin-Proteasome System , 2006, The Journal of Neuroscience.

[29]  L. Mucke,et al.  Phospholipase A2 reduction ameliorates cognitive deficits in a mouse model of Alzheimer's disease , 2008, Nature Neuroscience.

[30]  L. Mucke,et al.  Modulation of Alzheimer-Like Synaptic and Cholinergic Deficits in Transgenic Mice by Human Apolipoprotein E Depends on Isoform , Aging, and Overexpression of Amyloid β Peptides But Not on Plaque Formation , 2002, The Journal of Neuroscience.

[31]  R. Lal,et al.  Amyloid β protein forms ion channels: implications for Alzheimer's disease pathophysiology , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[32]  Bernardo L Sabatini,et al.  Natural Oligomers of the Alzheimer Amyloid-β Protein Induce Reversible Synapse Loss by Modulating an NMDA-Type Glutamate Receptor-Dependent Signaling Pathway , 2007, The Journal of Neuroscience.

[33]  W. Klein,et al.  Aβ Oligomer-Induced Aberrations in Synapse Composition, Shape, and Density Provide a Molecular Basis for Loss of Connectivity in Alzheimer's Disease , 2007, The Journal of Neuroscience.

[34]  Roberto Malinow,et al.  Amyloid beta from axons and dendrites reduces local spine number and plasticity , 2010, Nature Neuroscience.

[35]  L. Mucke,et al.  Enkephalin Elevations Contribute to Neuronal and Behavioral Impairments in a Transgenic Mouse Model of Alzheimer's Disease , 2008, The Journal of Neuroscience.

[36]  L. Mucke,et al.  Amyloid-β–induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks , 2010, Nature Neuroscience.

[37]  N. Arispe,et al.  The Cell-Selective Neurotoxicity of the Alzheimer's Aβ Peptide Is Determined by Surface Phosphatidylserine and Cytosolic ATP Levels. Membrane Binding Is Required for Aβ Toxicity , 2007, The Journal of Neuroscience.

[38]  M. Pangalos,et al.  Treatment strategies targeting amyloid β-protein. , 2012, Cold Spring Harbor perspectives in medicine.

[39]  C. Finch,et al.  Alzheimer's disease-affected brain: Presence of oligomeric Aβ ligands (ADDLs) suggests a molecular basis for reversible memory loss , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[40]  Y. Ihara,et al.  The ubiquitin-proteasome system and the autophagic-lysosomal system in Alzheimer disease. , 2012, Cold Spring Harbor perspectives in medicine.

[41]  D. Westaway,et al.  Cyclohexanehexol inhibitors of Aβ aggregation prevent and reverse Alzheimer phenotype in a mouse model , 2006, Nature Medicine.

[42]  S. Strittmatter,et al.  Memory Impairment in Transgenic Alzheimer Mice Requires Cellular Prion Protein , 2010, The Journal of Neuroscience.

[43]  D. Selkoe,et al.  The oligomerization of amyloid beta-protein begins intracellularly in cells derived from human brain. , 2000, Biochemistry.

[44]  Peter T. Lansbury,et al.  Observation of metastable Aβ amyloid protofibrils by atomic force microscopy , 1997 .

[45]  R. Anwyl,et al.  Use-Dependent Effects of Amyloidogenic Fragments of β-Amyloid Precursor Protein on Synaptic Plasticity in Rat Hippocampus In Vivo , 2001, The Journal of Neuroscience.

[46]  D. Selkoe,et al.  Natural oligomers of the amyloid-β protein specifically disrupt cognitive function , 2005, Nature Neuroscience.

[47]  M. Gobbi,et al.  Synthetic amyloid-β oligomers impair long-term memory independently of cellular prion protein , 2010, Proceedings of the National Academy of Sciences.

[48]  Julie A. Harris,et al.  Transsynaptic Progression of Amyloid-β-Induced Neuronal Dysfunction within the Entorhinal-Hippocampal Network , 2010, Neuron.

[49]  L. Mucke,et al.  Reducing Endogenous Tau Ameliorates Amyloid ß-Induced Deficits in an Alzheimer's Disease Mouse Model , 2007, Science.

[50]  L. Mucke,et al.  Amyloid-β/Fyn–Induced Synaptic, Network, and Cognitive Impairments Depend on Tau Levels in Multiple Mouse Models of Alzheimer's Disease , 2011, The Journal of Neuroscience.

[51]  Kang Hu,et al.  High-Level Neuronal Expression of Aβ1–42 in Wild-Type Human Amyloid Protein Precursor Transgenic Mice: Synaptotoxicity without Plaque Formation , 2000, The Journal of Neuroscience.

[52]  Todd E. Golde,et al.  Anti-Aβ Therapeutics in Alzheimer's Disease: The Need for a Paradigm Shift , 2011, Neuron.

[53]  Dominic M. Walsh,et al.  Protofibrillar Intermediates of Amyloid β-Protein Induce Acute Electrophysiological Changes and Progressive Neurotoxicity in Cortical Neurons , 1999, The Journal of Neuroscience.

[54]  L. Mucke,et al.  Ablation of Cellular Prion Protein Does Not Ameliorate Abnormal Neural Network Activity or Cognitive Dysfunction in the J20 Line of Human Amyloid Precursor Protein Transgenic Mice , 2011, The Journal of Neuroscience.

[55]  R. Malinow,et al.  APP Processing and Synaptic Function , 2003, Neuron.

[56]  B. Hyman,et al.  Neuropathological alterations in Alzheimer disease. , 2011, Cold Spring Harbor perspectives in medicine.

[57]  R. Mahley,et al.  Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[58]  S. DeKosky,et al.  Synapse loss in frontal cortex biopsies in Alzheimer's disease: Correlation with cognitive severity , 1990, Annals of neurology.

[59]  W. K. Cullen,et al.  Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo , 2002, Nature.

[60]  K. Duff,et al.  Behavioral Changes in Transgenic Mice Expressing Both Amyloid Precursor Protein and Presenilin-1 Mutations: Lack of Association with Amyloid Deposits , 1999, Behavior genetics.

[61]  Jürgen Götz,et al.  Dendritic Function of Tau Mediates Amyloid-β Toxicity in Alzheimer's Disease Mouse Models , 2010, Cell.

[62]  M. Sheng,et al.  Role of NMDA Receptor Subtypes in Governing the Direction of Hippocampal Synaptic Plasticity , 2004, Science.

[63]  J. Lorber Is your brain really necessary? , 1981, Nursing mirror.

[64]  C. Masters,et al.  Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease , 1999, Annals of neurology.

[65]  Steven Mennerick,et al.  Synaptic Activity Regulates Interstitial Fluid Amyloid-β Levels In Vivo , 2005, Neuron.

[66]  K. Ashe,et al.  Tau Mislocalization to Dendritic Spines Mediates Synaptic Dysfunction Independently of Neurodegeneration , 2010, Neuron.

[67]  John W. Gilbert,et al.  Cellular Prion Protein Mediates Impairment of Synaptic Plasticity by Amyloid-β Oligomers , 2009, Nature.

[68]  L. Mucke,et al.  Alzheimer's disease: Apolipoprotein E and cognitive performance , 2000, Nature.

[69]  I. Bezprozvanny,et al.  The dysregulation of intracellular calcium in Alzheimer disease. , 2010, Cell calcium.

[70]  D. Selkoe Alzheimer's Disease Is a Synaptic Failure , 2002, Science.

[71]  J. Trojanowski,et al.  Intraneuronal APP, Not Free Aβ Peptides in 3xTg-AD Mice: Implications for Tau versus Aβ-Mediated Alzheimer Neurodegeneration , 2011, The Journal of Neuroscience.

[72]  Ian Parker,et al.  Calcium Dysregulation and Membrane Disruption as a Ubiquitous Neurotoxic Mechanism of Soluble Amyloid Oligomers*♦ , 2005, Journal of Biological Chemistry.

[73]  M. Emmerling,et al.  Morphology and Toxicity of Aβ-(1-42) Dimer Derived from Neuritic and Vascular Amyloid Deposits of Alzheimer's Disease* , 1996, The Journal of Biological Chemistry.

[74]  A. Aguzzi,et al.  Supplementary figure legends , 2010 .

[75]  Sylvain Rheims,et al.  Amyloid β-Induced Neuronal Hyperexcitability Triggers Progressive Epilepsy , 2009, The Journal of Neuroscience.

[76]  G. Bitan,et al.  Amyloid (cid:1) -Protein Oligomerization PRENUCLEATION INTERACTIONS REVEALED BY PHOTO-INDUCED CROSS-LINKING OF UNMODIFIED PROTEINS* , 2001 .

[77]  Mikio Shoji,et al.  Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease , 2001, The Journal of Neuroscience.

[78]  S. Yan,et al.  Amyloid-β-Induced Mitochondrial Dysfunction , 2007 .

[79]  L. Mucke,et al.  Imbalance between GABAergic and Glutamatergic Transmission Impairs Adult Neurogenesis in an Animal Model of Alzheimer's Disease. , 2009, Cell stem cell.

[80]  E. Kandel,et al.  Loss of Presenilin Function Causes Impairments of Memory and Synaptic Plasticity Followed by Age-Dependent Neurodegeneration , 2004, Neuron.

[81]  R. Brandt,et al.  Divergent Pathways Mediate Spine Alterations and Cell Death Induced by Amyloid-β, Wild-Type Tau, and R406W Tau , 2009, The Journal of Neuroscience.

[82]  M. Rowan,et al.  Alzheimer's Disease Brain-Derived Amyloid-β-Mediated Inhibition of LTP In Vivo Is Prevented by Immunotargeting Cellular Prion Protein , 2011, The Journal of Neuroscience.

[83]  I. Slutsky,et al.  Amyloid-β as a positive endogenous regulator of release probability at hippocampal synapses , 2009, Nature Neuroscience.

[84]  L. Mucke,et al.  A network dysfunction perspective on neurodegenerative diseases , 2006, Nature.

[85]  B. Hyman,et al.  Tau Suppression in a Neurodegenerative Mouse Model Improves Memory Function , 2005, Science.

[86]  Phillip B. Jones,et al.  Impaired spine stability underlies plaque-related spine loss in an Alzheimer's disease mouse model. , 2007, The American journal of pathology.

[87]  Shaomin Li,et al.  Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory , 2008, Nature Medicine.

[88]  S. Younkin,et al.  Age-Dependent Changes in Brain , CSF , and Plasma Amyloid b Protein in the Tg 2576 Transgenic Mouse Model of Alzheimer ’ s Disease , 2001 .

[89]  R. Anwyl,et al.  Block of Long-Term Potentiation by Naturally Secreted and Synthetic Amyloid β-Peptide in Hippocampal Slices Is Mediated via Activation of the Kinases c-Jun N-Terminal Kinase, Cyclin-Dependent Kinase 5, and p38 Mitogen-Activated Protein Kinase as well as Metabotropic Glutamate Receptor Type 5 , 2004, The Journal of Neuroscience.

[90]  Seiji Nishino,et al.  Amyloid-β Dynamics Are Regulated by Orexin and the Sleep-Wake Cycle , 2009, Science.

[91]  R. D'Hooge,et al.  Lipids revert inert Aβ amyloid fibrils to neurotoxic protofibrils that affect learning in mice , 2007, The EMBO Journal.

[92]  C. Almeida,et al.  Intraneuronal Aβ accumulation and origin of plaques in Alzheimer's disease , 2005, Neurobiology of Aging.

[93]  A. Palmeri,et al.  Picomolar Amyloid-β Positively Modulates Synaptic Plasticity and Memory in Hippocampus , 2008, The Journal of Neuroscience.

[94]  J. Growdon,et al.  Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology. , 2010, Brain : a journal of neurology.

[95]  E. Mandelkow,et al.  Aβ Oligomers Cause Localized Ca2+ Elevation, Missorting of Endogenous Tau into Dendrites, Tau Phosphorylation, and Destruction of Microtubules and Spines , 2010, The Journal of Neuroscience.

[96]  T. Morgan,et al.  Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[97]  W. K. Cullen,et al.  Amyloid β protein immunotherapy neutralizes Aβ oligomers that disrupt synaptic plasticity in vivo , 2005, Nature Medicine.

[98]  J. David Sweatt,et al.  β-Amyloid Peptide Activates α7 Nicotinic Acetylcholine Receptors Expressed in Xenopus Oocytes* , 2002, The Journal of Biological Chemistry.

[99]  D. Selkoe,et al.  Resolving controversies on the path to Alzheimer's therapeutics , 2011, Nature Medicine.

[100]  J Carter,et al.  Molecular Pathology of Alzheimer's Disease , 2013 .

[101]  Jacob Raber,et al.  Neuronal depletion of calcium-dependent proteins in the dentate gyrus is tightly linked to Alzheimer's disease-related cognitive deficits , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[102]  P. Greengard,et al.  Regulation of NMDA receptor trafficking by amyloid-beta. , 2005, Nature neuroscience.

[103]  S. Squazzo,et al.  Aggregation of Secreted Amyloid -Protein into Sodium Dodecyl Sulfate-stable Oligomers in Cell Culture (*) , 1995, The Journal of Biological Chemistry.

[104]  R. Mantegna,et al.  Quantitative analysis of senile plaques in Alzheimer disease: observation of log-normal size distribution and molecular epidemiology of differences associated with apolipoprotein E genotype and trisomy 21 (Down syndrome). , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[105]  J. Hardy,et al.  Alzheimer's disease: the amyloid cascade hypothesis. , 1992, Science.

[106]  D. Salmon,et al.  Physical basis of cognitive alterations in alzheimer's disease: Synapse loss is the major correlate of cognitive impairment , 1991, Annals of neurology.

[107]  D. Selkoe,et al.  Soluble amyloid β-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration , 2011, Proceedings of the National Academy of Sciences.

[108]  S. Estus,et al.  Production of the Alzheimer amyloid beta protein by normal proteolytic processing. , 1992, Science.

[109]  M. Gallagher,et al.  A specific amyloid-β protein assembly in the brain impairs memory , 2006, Nature.

[110]  Anatol C. Kreitzer,et al.  Aberrant Excitatory Neuronal Activity and Compensatory Remodeling of Inhibitory Hippocampal Circuits in Mouse Models of Alzheimer's Disease , 2007, Neuron.

[111]  D. Walsh,et al.  Amyloid beta-protein fibrillogenesis. Detection of a protofibrillar intermediate. , 1997, The Journal of biological chemistry.

[112]  Julie R. Leitz,et al.  Tau Protein Is Required for Amyloid β-Induced Impairment of Hippocampal Long-Term Potentiation , 2011, The Journal of Neuroscience.